Healthcare tech firm Indegene has announced the acquisition of BioPharm, a Pennsylvania-based specialised marketing services agency and part of Omnicom Health Group, for $106 million. BioPharm delivers marketing and communications solutions to life sciences clients across North America.
Acquisition to boost Indegene’s AI led pharma marketing portfolio
The deal, executed through Indegene’s subsidiary ILSL Inc., aims to strengthen Indegene’s commercialisation portfolio and expand its AI-powered marketing and AdTech capabilities for global pharmaceutical companies. BioPharm, which employs more than 90 people in the US, reported revenues of $38.13 million in 2024 and specialises in data-driven healthcare provider marketing solutions.
BioPharma brings top global biopharma clients to Indegene
BioPharm’s client roster includes 17 of the world’s top 25 biopharma companies. The agency offers expertise in omnichannel strategy, end-to-end media journeys, analytics, automation, and targeted engagement. “This acquisition reinforces our position as the preferred tech-native commercialisation partner for the life sciences industry,” said Manish Gupta, chairman and CEO of Indegene.
As market dynamics shift and regulatory landscapes grow more complex, pharmaceutical companies are seeking to transform their commercialisation processes. Traditional healthcare agencies have struggled to keep pace with the rapidly evolving expectations of pharma clients, driving demand for specialised solution providers like Indegene, which emphasise co-innovating commercialisation models with an AI-first, data-driven approach.
Indegene highlighted the significance of the acquisition amid an environment where pharmaceutical companies manage both mature and growth product portfolios while ramping up capabilities for new drug launches. This comes as physicians increasingly favour limited engagement models, accelerating the adoption of innovative digital engagement strategies.
